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a b s t r a c t
The presence of different forms of histone covalent modiﬁcations, such as phosphorylation, acetylation
and methylation in localized promoter regions are markers for chromatin packing and transcription.
Activation of RAS signalling pathways through oncogenic RAS mutations is a hallmark of colorectal can-
cer. Overexpression of Harvey-Ras oncogene induces epithelial–mesenchymal transition (EMT) in Caco-2
cells. We focused on the role of epigenetic modiﬁcations of histone H3 and its dependence on RAS signal
transduction pathways and oncogenic transformation. Using cell lines stably overexpressing oncogenic
Harvey-RAS with EMT phenotype, we studied the acquired changes in the H3 histone modiﬁcation pat-
terns. Two genes show inverse protein expression patterns after Ha-RAS overexpression: Cyclin D1, a
cell cycle-related gene, and the EMT marker-gene E-cadherin. We report that these two genes demon-
strate matching inverse histone repression patterns on their promoter, while histone markers associatedSK1 with an active state of genes were affected by the RAS-activated signalling pathway MEK–ERK–MSK1.
Furthermore, we show that though the level of methyltransferases enzymes was increased, the status
of H3 three-methylation at lysine 27 (H3K27me3), associated with gene repression on the promoter of
Cyclin D1, was lower. Together, these results suggest that histone covalent modiﬁcations can be affected
by oncogenic RAS pathways to regulate the expression of target genes like Cyclin D1 or E-cadherin and
that the dynamic balance of opposing histone-modifying enzymes is critical for the regulation of cell
proliferation.
. Introduction
In colorectal cancer, alterations in the activity of tumor suppres-
or genes and oncogenes are accompanied by reversible epigenetic
hanges, which result in inheritable gene function modiﬁcations
nd lack of DNA sequence alterations. Different forms of epige-
etic mechanisms have been shown to modify the expression
f key genes during colorectal tumor progression. Global DNA
ypomethylation (Feinberg and Vogelstein, 1983), as well as hypo-
nd hypermethylation of speciﬁc DNA regions in promoters of
ncogenes (Nakamura and Takenaga, 1998), tumor suppressor (Di
Abbreviations: EMT, epithelial–mesenchymal transition; AP-1, activating pro-
ein 1; MAPK, mitogen-activated protein kinase; HAT, histone acetyltransferase;
DAC, histone deacetylase; ChIP, chromatin immunoprecipitation.
∗ Corresponding author at: National Hellenic Research Foundation, 48, Vas. Con-
tantinou Ave., 11635 Athens, Greece. Tel.: +30 2107273753; fax: +30 2107273755.
E-mail address: apint@eie.gr (A. Pintzas).
357-2725/$ – see front matter © 2010 Elsevier Ltd. All rights reserved.
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et al., 2002) andmismatch repair genes (Edelmannet al., 1997) con-
tribute to tumor progression. Epigenetic changes have also been
described to play a role in chromosomal instability (Suter et al.,
2004) or in loss of gene imprinting, which occurs at the earliest
stages of colorectal neoplasia causing abnormal gene expression
(Sakatani et al., 2005) and is as well mediated by DNA methylation
and covalent histone modiﬁcations. Histone covalent modiﬁca-
tions such as acetylation, methylation and phosphorylation are
distributed along promoters, on coding and intergenic regions
modifying chromatin structure. Patterns of speciﬁc histone mod-
iﬁcations constitute the “histone code” (Berger, 2002) that controls
the recruitment of many factors in processes such as transcrip-
tion, DNA repair or DNA replication. In general, acetylations of
histone H4 and H3 on lysines 9 and 14 (H3K9/14ac), phosphory-
lation of histone H3 at serine 10 (H3S10p), and trimethylation of
histone H3 at lysine 4 (H3K4me3) are considered to be marks of
gene expression activation. On the other hand, di- or trimethyla-
tions of histone H3 lysine 9 (H3K9me2, H3K9me3) and lysine 27
(H3K27me3) have been linked to gene repression (Barski et al.,
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007). However, different modiﬁcations can have different effects
epending on the chromatin context, while studies have presented
crosstalk among different histone modiﬁcations (Wang et al.,
008).
Epigenetic deregulation may affect different aspects of tumor
rogression and could be linked to patient prognosis. The global
attern of histone modiﬁcations has been reported as a risk-
redictor for the tumor recurrence in prostate, gastric, breast and
ancreas cancer patients (Seligson et al., 2005; Park et al., 2008a,b;
raga et al., 2005). Moreover, changes in genes encoding proteins
hat participate in acetylation and methylation of H3 and H4 lysine
esidues have also been found inmany types of tumors (Varambally
t al., 2002; Kirmizis et al., 2003).
In the case of colorectal cancer, activationof signallingpathways
nduced by Ki-RAS or BRAF mutations regulates cell proliferation,
poptosis and several other cellular processes. Deregulation of
hese signalling pathways might result in epigenetic alterations,
s well. In parallel, oncogenic Ha-RAS-transformed cells have been
hown to acquire characteristics of cells that have undergone
pithelial–mesenchymal transition (EMT) (Voulgari et al., 2008;
ndreolas et al., 2008) and express stem cell markers (Morel et al.,
008). EMT is a developmental programme that has been related to
ancer invasion andmetastasis (Thiery and Sleeman, 2006). Consti-
utive activation of the RAS–MAPK pathway by oncoproteins leads
o an increase in the H3S10p steady-state level through activation
f ERK1/ERK2 or the p38 stress-signalling pathway (Dyson et al.,
005). Elevated level ofH3S10p is associatedwith transcription and
s observed in RAS-transformed cells (Chadee et al., 1999). Among
everal kinases, the stimuli-dependent MSK1/MSK2 (Drobic et al.,
004; Soloaga et al., 2003) and RSK2 (Trivier et al., 1996) have been
escribed to be responsible for H3S10 phosphorylation. Moreover,
everal histone acetyltransferases (HATs), among which GCN5 or
CAF, have been shown to exhibit increased activity, both in vitro
nd in vivo, on H3 peptides which are phosphorylated on Ser-10
Lo et al., 2000).
Cyclin D1 is overexpressed in adenocarcinomas (Sutter et al.,
997) and contributes to colonic tumor growth in colorectal cancer
Hulit et al., 2004). Various studies have characterized Cyclin D1 as
characteristic RAS target gene, while its promoter cis-elements
ave shown involvement in its RAS-dependent activation. The pro-
oter region of the Cyclin D1 gene contains binding sites for AP-1
Albanese et al., 1999), CREB, SP1 (Nagata et al., 2001; Hilton et
l., 2005), ATF/CREB (Lee et al., 1999) and NFkB (Joyce et al., 1999),
hoseaccessibility andoccupancyby thecognate transcription fac-
ors depend on the chromatin structure and histone modiﬁcations.
nother gene implicated in tumor growth is E-cadherin,whose loss
f expression correlates with tumor progression and metastasis.
ownregulation of the expression levels of E-cadherin has been
ssociated with central cellular pathways such as TGF, -catenin
r the Wnt signalling, while hypermethylation of the E-cadherin
romoter has been linked to promoter-silencing and therefore to
arcinogenesis and EMT (Bolos et al., 2003; Comijn et al., 2001;
onacci-Sorrell et al., 2003).
In this study,we focused onunderstanding the role of global his-
one modiﬁcations in a model of colorectal cancer and how these
odiﬁcations may be affected by pathways activated by onco-
enes: Ha-Ras, Ki-Ras and BRAF. Transformed Caco-2 cells by these
ncogenes showed aggressive phenotype with respect to Caco-2
arent cells. We found that two genes, Cyclin D1 and E-cadherin,
howed inverse mRNA and protein expression levels after stable
verexpressionof their activated forms.Wedeliver evidence show-
ng that the two genes Cyclin D1 and E-cadherin are reversely
egulated by histone modiﬁcations in a RAS-dependent manner.
inally, we suggest that histone H3 K9/K14 acetylation levels on
yclin D1 promoter are regulated by the MEK–ERK–MSK1 path-
ay.iochemistry & Cell Biology 42 (2010) 911–920
2. Materials and methods
2.1. Cell lines
The Caco-2 cell line was supplied by the American Type Culture
Collection (Manassas, VA, USA). Caco-2, an intermediate ade-
nocarcinoma cell line, does not contain RAS mutations. Caco-2
stable-transfected cell lines with oncogenic Kirsten- (referred to
as Caco-K6 and Caco-K15) Harvey-RAS (referred to as Caco-H1 and
Caco-H2) (Roberts et al., 2006) BRAF genes (referred to as Caco-
Br13 and Caco-Br23) and empty vector (referred to as Caco-neo)
(Oikonomou et al., 2009) have been previously established in our
lab. Cells were cultured in a humidiﬁed atmosphere at 37◦ C with
5% CO2 and grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
(InvitrogenLifeTechnologies, Carlsbad, CA) supplementedwith10%
foetal bovine serum (FBS) (Invitrogen), 1% penicillin/streptomycin
(Invitrogen) and non-essential amino acids (Invitrogen).
2.2. Protein kinase inhibitors
Caco-H2 cells were treated with MEK inhibitor UO126
(5–40M) (Alexis Biochemicals, CA) to block MEK–ERK pathway.
Cells were incubated with inhibitor for 1–4 and 6h. In parallel,
Wortmanin (5M) (Alexis Biochemicals) was added to block AKT
signalling pathway at the same time points. The cells were plated
on 6-well plates in DMEM+10% FBS and collected, and total lysates
were loaded on a 10% PAGE gel. MSK1 kinase activity was blocked
by adding H89 inhibitor (10M) (Alexis Biochemicals) and again
total extracts were prepared as described in previous studies.
2.3. Cell extracts—Western blot
Total extracts were prepared from cells that were grown in 10-
cm Petri dishes, washed 3 times with ice cold phosphate-buffered
saline (PBS) and collected in ice cold lysis buffer (50mM Tris–HCl,
pH 7.4, 250mM sucrose, 1mM EDTA, 10mM NaF, 1mM EGTA,
and 1% Triton X-100 plus protease inhibitors). Acid extractions
of histone proteins were performed in resuspending cells, after a
3-time wash with PBS, in Triton extraction buffer (TEB; PBS con-
taining 0.5% Triton X-100 (v/v), 2mM PMSDF, 0.02% NaN3) and
kept on ice for 10min. Nuclei were collected with a centrifuga-
tion at 6500× g for 10min at 4 ◦C and were resolved in TEB once
more and after centrifugation they were resuspended in 0.2N HCl.
After an o/n incubation, the cells were centrifuged at 6500×g for
10min resulting in a supernatant containing the histone proteins.
Extracts were resolved on SDS-PAGE (10 or 12% w/v acrylamide),
transferred to nitrocellulosemembranes (BioTraceNT; Pall Life Sci-
ences, NY) and immunoblotwith appropriate antibodies proceeded
overnight. Standard chemiluminescence protocol was applied to
visualize the proteins by using horseradish peroxidase conju-
gated anti-rabbit IgG or anti-mouse IgG (Jackson Immunoresearch
Laboratories, West Grove, PA) and enhanced chemiluminescence
detection system (ECL) (Amersham Biosciences, Buckinghamshire,
UK).
2.4. Immunoﬂuorescence
Cell cultures were ﬁxed with 4% paraformaldehyde, washed,
permeabilized with 0.3% Triton X-100 and blocked with 5% BSA
prior to incubation with primary antibodies (H3K9–14ac, 1:500,
Upstate; H3S10P, 1:200, Santa Cruz Biotechnology; H3K4me3,
1:2000, Abcam; H3K9me2, 1:500, Abcam; H4K12ac, 1:500 Abcam;
H3K27me3, 1:500, Abcam; p-MSK1, 1:500, Abcam; p-ERK, 1:500,
Santa Cruz Biotechnology; Aurora A, 1:500, BD Biosciences; GCN5,
1:100, Santa Cruz Biotechnology; PCAF, 1:100, Santa Cruz Biotech-
nology, JMJD3, 1:200, Abgent; EZH2, 1:500, BD Biosciences). Cells
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ere then stained with Alexa488- or Alexa555-conjugated sec-
ndary antibodies (Molecular Probes). The nuclei counterstained
ith DAPI and the samples were mounted in Vectashield (Vector
abs).
.5. RNA extraction and real-time PCR
Total RNA extraction was isolated with TRIZOL reagent (Invit-
ogen) and reverse transcribed to cDNA with SuperscriptRT
ranscriptase II (Invitrogen). Real-time PCR was carried with spe-
iﬁc primers and expression was normalized with GADPH. Primer
airs (5′–3′) were: PCAF: GCC CTA GCT GCT CAT GTT TC and GGT
TT TCA AAT GGG GGT TT; GCN5: CTA TGG GGC AAA CTC TCC AA
nd ATC CTC CAG GGT CAG GTT CT; EZH2: CAT AAT GTA TTC TTG
TC TCC C and AAA CCC ACA TTC TCT ATC CC; JMJD3: GAA ACC
AA GAT CAA CAC TG and TTG CTC TCC AGA TAG ATG CT; GADPH:
AA GGT GAA GGT CGG AGT and CAT GGG TGG AAT CAT ATT GGA
; HDAC9: GGC TCAG CTT CAG GAG CAT A and CTT CCT GTT CTT
CC TCT GC; primer used for HDAC4, HDAC5 and HDAC7 was in
ccordance with Ozdag˘ et al. (2006).
The reactionwas carried in 96-well plates (BioRad, Hercules, CA,
SA). PCR reactions were run in triplicate in the presence of SYBR-
reen (BioRad). Melting curve analyses revealed a single product.
nalysiswas done using iCycler iQreal-timeDetection System soft-
are (BioRad). The experiment was repeated twice for each gene
nd cell line. Standard deviation bars for each histogram were cal-
ulated automatically by the software of real-time machine based
n the standard deviation of the triplicate both for GAPDH and for
he target genes.
.6. ChIP
Chromatin immunoprecipitation was performed essentially as
escribed previously (Voulgari et al., 2008). Pre-cleared chromatin
as incubated overnight by rotation with 2g of antibody (p-
un, Santa Cruz Biotechnology; H3K9–14ac, Upstate; H3K27me3,
pstate; H3K9me2, Upstate; H3K9–14ac and H3K4me3, Abcam;
zH2, BD Biosciences) or no antibody as a negative control.
mmunoprecipitates were resuspended in 40l TE buffer whereas
nputs were resuspended in 90l TE buffer. Inputs and immuno-
recipitated DNA samples were quantiﬁed by real-time PCR. The
eaction was carried in 96-well plates (BioRad) and PCR reactions
ere run in triplicate in the presence of SYBR-Green (BioRad).
ycling conditions include: denaturing step of 3min at 95 ◦C fol-
owed by 40 cycles of 30 s at 95◦; and annealing/elongation at
4 ◦C. Ct values of the immunoprecipitated samples were normal-
zed with Ct input values. GADPH was used as an internal control.
he experiment was repeated twice for each histone modiﬁca-
ion. Cyclin D1 promoter primers for real-time PCR were: 5′-ATG
CC AGG GCA AAT TCT AAA-3′ and 5′-ACA CAC CTC TGA ATG GAA
GC-3′; E-cadherin promoter primers for real-time PCR were: 5′-
CTGATCCCAGGTCTTAGTG-3′ and 5′-GGCTGGAGCGGGCTGGAG-3′
.7. siRNA transfection assay
Plasmid DNA was transfected into cells by the calcium
hosphate method that has been described previously (Chen
nd Okayama, 1987). For the transfection of siRNA, cells were
reated with human siGenome ON-TARGET plus SMARTpool
-Jun (L-003268-00-0020) according to the manufacturer’s pro-
ocol (Dharmacon, Chicago, IL). 48h after transfection cells were
arvested. Total protein extracts and RNA were extracted as
escribed previously. To distinguish sequence-speciﬁc silencing
rom non-speciﬁc effects, negative controls were performed by
sing siCONTROL RISC-free siRNA (D-001210-03).iochemistry & Cell Biology 42 (2010) 911–920 913
3. Results
3.1. Global levels of histone modiﬁcations in colon
adenocarcinoma cell lines
To understand how patterns of global histone modiﬁcations are
altered by activated oncogenes, we studied histone modiﬁcations
in adenocarcinoma cell lines that have been stably transformed
with the oncogenic form of Ha-RAS (Caco-H), Ki-RAS (Caco-K) and
BRAF (Caco-BR). Immunostaining with antibodies speciﬁc for his-
tone markers associated with active genes such as H3K9–14ac,
H3S10P and H3K4me3 indicated (Fig. 1A and D) a slight increase
in the levels of H3S10P and H3K4me3 levels in both Caco-H and
Caco-K cells as compared to the non-transformed cell line Caco-
2. On the other hand, immunostaining with antibodies speciﬁc
for histone markers associated with repressed genes showed that
the levels of H3K27me3 were reduced in the Caco-H cell line
as compared to the Caco-2 cells (Fig. 1B and D). Interestingly,
at the same time, in the Caco-H cells, which are cells that have
undergone an epithelial–mesenchymal transition (EMT), a unique
distribution pattern of H3K27me3 was observed, as the stain-
ing was lost in the perinuclear area and appeared as a granular
pattern in the central nuclear area (Fig. 1C). To evaluate the dif-
ferences on the global levels of histone modiﬁcations observed by
immunostaining,weanalyzed their levels byWesternblot (Fig. 1D).
Similarly, H3K27me3 levels (associated with a repressed state of
genes) were decreased in Caco-H cells while H3S10P and H3K4me3
levels (associated with an active state of genes) were increased
in the same cell line as compared to Caco-2 cells, indicating an
inverse regulatory function of global histone modiﬁcation levels
in relation with the expression of oncogenic Ha-RAS and with
EMT.
3.2. Levels of histone-modifying enzymes are affected by
oncogenic Ha-RAS
In order to clarify the pathway followed for the changes
in the global histone modiﬁcations in the cell lines studied,
we determined the mRNA and protein levels of GCN5, PCAF,
acetyltransferases, EzH2 histone methyltransferase and JMJD3
demethylase by Western blot and real-time PCR analysis (Fig. 2A
and B). Notably, the H3K27me3-speciﬁc methyltransferases EZH2
and JMJD3 were upregulated in the two cell lines overexpressing
the oncogenic Ha-RAS protein (Caco-H1 and Caco-H2) both in pro-
tein and mRNA levels, indicating a possible involvement of these
two histone methyltransferases in the regulation of the decreased
global levels of H3K27me3 in cells overexpressing the mutant Ha-
RAS gene and thus undergoing EMT. GCN5, PCAF acetyltransferase
enzymes also showed increased protein and mRNA levels overall
in Caco-BR clones. In Fig. 2C we present a comparison between
Caco-neo, empty vector containing cells, Caco-2 and Caco-H2 cells.
In these cells we analyzed by immunoﬂuorescence and confocal
microscopy the protein levels of EzH2 and JmJD3 and the histone
modiﬁcation H3K27me3. Caco-H2 cells showed variation, both for
the proteins and the status of three-methylation of the lysine 27 of
histone H3 as well as for EzH2 and JmJD3 and the histone markers
H3K27me3 and H3K9–14ac as compared to Caco-2 and Caco-neo
cells.
3.3. MEK signalling regulates global H3K9/14ac levels in Ha-RAS
transfected Caco-2 cellsIn Caco-H cells the MEK/ERK and AKT pathways were shown to
be highly activated (Fig. 3A) as compared to the Caco-2 cell line.
In order to study the relation between the histone modiﬁcation
which is associated with increased gene expression (H3K9–14ac)
914 I. Mazón Peláez et al. / The International Journal of Biochemistry & Cell Biology 42 (2010) 911–920
Fig. 1. Global histone modiﬁcation levels in cell lines overexpressing the oncogenic Ha-RAS, Ki-RAS and BRAF protein. (A) Immunoﬂuorescence confocal imaging of histone
modiﬁcationmarkers associatedwith activated genes in Caco-2, Caco-H, Caco-K and Caco-BR cells. (B) Immunoﬂuorescence confocal imaging of histonemodiﬁcationmarkers
associatedwith repressed genes in Caco-2, Caco-H, Caco-K and Caco-BR cells. Nucleiwere stainedwithDAPI.Merged images are shown (magniﬁcation 63×). (C)Magniﬁcation
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sf a Caco-2 versus Caco-H cell stained with the histone modiﬁcation marker H3K27m
f histone markers in the above-mentioned cell lines. Numbers below the WB band
nd Ha-RAS overexpression, we followed with the analysis of the
nvolvement of theMEK/ERKpathway in this speciﬁc phenomenon.
reatment of Caco-H cells with the MEK inhibitor UO126 (40M)
n a time-course of 6h resulted in a decrease in p-ERK protein lev-
ls after 1h of treatment (Fig. 3C, E and F). To demonstrate that
ff-target effects due to high concentration of UO126 do not affect
istone modiﬁcations, we treated Caco-H cells with different con-
entration of UO126 (5, 10, 20 and 40M) for 1 and 2h. For each
oint we performed a Western blot analysis and the expression
evels of p-ERK, p-MEK, Cyclin D1 and H3K9–14ac are presented in
ig. 3B. The inhibition of p-ERK begins also with concentration as
ow as 5M, which however is not sufﬁcient to block p-ERK for a
ong time in Caco-H cells. Indeed, after 1h, and perhaps also earlier,
he status of p-ERK becomes normal. No changes in p-MEK, Cyclin
1 and H3K9–14ac appeared within 2h of treatment with any con-
entrationofUO126. In fact, the levels ofH3K9/14acdecreasedafter
h of UO126 treatment at 40M, following the downregulation
f p-ERK (Fig. 3C). At the same time, to investigate the effect of
EK–ERK–MSK1 pathway on H3K9–14ac, we inhibited the kinase
ctivity ofMSK1by treating the cells by speciﬁcMSK1 inhibitorH89
10M). In this case, global levels of H3K9/14ac decreased after
h of MSK1 inactivation (Fig. 3D). Under the same conditions, PI3
inase had no effects on the global levels of H3K9–14ac (data not
hown) indicating that the speciﬁc participation of the MEK/ERK
athway in the regulation of the active global histone modiﬁcation
evels.
.4. Two Ha-RAS target genes show inverse histone repression
atterns on their promoter
Cyclin D1 and E-cadherin are two genes that are inversely reg-
lated between Caco-2 and Caco-H cell lines as observed both at
rotein level by Western blot analysis and at mRNA level through
eal-time PCR analysis (Fig. 4A, left and right). Therefore, they
ere selected as ‘marker-genes’ in order to analyze in detail the
peciﬁc histone modiﬁcation alterations on gene promoters dur-dicating the differential localization pattern. (D) Western blot analysis of the levels
esent the value of quantiﬁcation of the spots normalized to total histone H3.
ing cancer progression by ChIP analysis. Interestingly, the analysis
of the histone markers that are associated with the repressed
state of genes (H3K27me3 and H3K9me2), when comparing the
intermediate adenoma cell line Caco-2 and its EMT-like derivative
Caco-H, showed an inverse pattern on the two promoters (Cyclin
D1 andE-cadherin) (Fig. 4B, left). On the CyclinD1promoter,whose
expression is increased in Caco-H cells, the levels of H3K27me3 and
H3K9me2 were signiﬁcantly lower on its promoter, as compared
to Caco-2 cells. We performed further ChIP analysis for the his-
tone methylase association EzH2 on the Cyclin D1 promoter. The
results obtained conﬁrm and help to demonstrate that although
in Caco-H cells there is an increase of EzH2 protein expression,
the three-methylation level in K27 of histone H3 in the promoter
region of Cyclin D1 is lower with respect to Caco-2 cells. In fact
as shown in Fig. 4B right, there is an increase of EZH2 on the pro-
moter region of Cyclin D1 in Caco-2 cells with respect to Caco-H.
On the other hand, on the promoter of E-cadherin, the expres-
sion of which is almost abolished in Caco-H cells, the levels of the
histone marks associated with repressed genes were signiﬁcantly
higher in Caco-H cells as compared to Caco-2 cells. At the same
time, the analysis of the histone marks associated with the active
state of genes (H3K4me3 and H3K9/14ac) was indeed, as expected,
downregulated on the promoter of E-cadherin in Caco-H cells as
compared to Caco-2 cells (Fig. 4B, left). Surprisingly in the case of
the Cyclin D1 promoter the levels of the active histone markers
were slightly downregulated, indicating a more complicated regu-
lation pattern of the active/repressed state of this particular gene in
Caco-H cells. To clarify the reason for downregulation of active his-
tone markers on Cyclin D1 promoter we analyzed the expression
of 4 class II histone deacetylase (HDAC) by real-time PCR. In Fig. 4C
are shown the results of expression analysis for HDAC4, HDAC5,
HDAC7 and HDAC9. In Caco-H cells all these 4 histone deacety-
lase enzymes are upregulated. In particular, HDAC7 and HDAC9
are strongly induced in Caco-H cells, where the value in the case of
HDAC9 in Caco-H1 cells reaches 80-fold as compared with Caco-2
cells.
I. Mazón Peláez et al. / The International Journal of Biochemistry & Cell Biology 42 (2010) 911–920 915
Fig. 2. The levels of certain histone-modifying enzymes change upononcogenicHa-RAS overexpression. Total protein (A andB)mRNA levels of GCN5, PCAF, acetyltransferases
andEzH2and JMJD3histonemethyltransferasesbyWesternblot and real-timePCRanalysis, respectively.Valueswerenormalized toGAPDH. (C) Immunoﬂuorescenceconfocal
imaging and Western blot analysis comparison between Caco-2 parent cell lines and Caco-neo cells. Numbers below the WB bands represent the value of quantiﬁcation of
the spots normalized to tubulin and total histone H3.
916 I. Mazón Peláez et al. / The International Journal of Biochemistry & Cell Biology 42 (2010) 911–920
Fig. 3. H3K9–14ac global levels are altered byRAS-activatedMEK–ERK signalling pathway. (A) Transfected Caco-2 cell linewith oncogenicHa-RAS (Caco-H) showed increased
levels of p-AKT and p-ERK in total protein extracts. (B) Dose–response curve of ERK1/2 inhibitor UO126. (C) UO126 (40M) was added to the cells and extracts were prepared
after 1–4 and 6h of incubation. Reduction of H3K9–14ac in the Caco-2 and Caco-H cell line was observed after 3-h incubation. (D) Western blot indicates alteration of global
H tivity.
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-ERK and p-MSK1 is shown, followed by immunocytochemistry and confocal micr
f the spots normalized to tubulin.
.5. Histone H3 K9/K14 acetylation levels on the Cyclin D1
romoter are regulated by MEK–ERK–MSK1 pathway
Further on, we wanted to understand in more detail the interre-
ation between the Ha-RAS-activated pathways and the presence
f the active mark H3K9/14ac on the promoter of Cyclin D1. With
hese means, we analyzed the dependence of H3K9/14ac presence
n the promoter of Cyclin D1, on a pathway highly activated in
a-Ras overexpressing cells (Caco-H), namely the MEK–ERK–MSK
athway. Thus, we blocked the MEK–ERK pathway in Caco-H cells
sing the UO126 inhibitor at a ﬁnal concentration of 40M. To fol-
ow Cyclin D1 expression we used Western blots (Fig. 5A, right),
hile the H3K9/K14ac levels on the promoter region were deter-
ined by ChIP (Fig. 5A, left and central). The results obtained
ndicate that blocking the MEK–ERK pathway reduced both the
cetylated H3K9/14ac levels on the Cyclin D1 promoter as well as
he Cyclin D1 expression levels. In order to obtain further conﬁr-
ation for the role of MEK–ERK–MSK1 pathway, we used the H89
nhibitor (10M) to inhibit MSK1 activity, which resulted simi-
arly in decreased levels of H3K9/14ac on the Cyclin D1 promoter
Fig. 5B, right) verifying the hypothesis of a MEK–ERK–MSK1 path-ATF2, a MSK1 target, has been used as control. (E and F) Reduction of H3K9–14ac,
y observation. Numbers below the WB bands represent the value of quantiﬁcation
way related regulation of the H3K9–14ac levels on the promoter of
Cyclin D1 (Fig. 5B).
3.6. H3K9–14ac binding on Cyclin D1 promoter partially depends
on c-Jun
Cyclin D1 is a gene of which promoter activity has been shown
to be closely related to its potential consensus AP-1 binding sites
(Herber et al., 1994; Shen et al., 2008). Particularly c-Jun, the pre-
dominant AP-1 protein and the major dimerizing partner has been
shown, in previous studies, to bind on the AP-1 sites of Cyclin D1
suggesting a regulatory function on its transcription (Bakiri et al.,
2000; Shaulian and Karin, 2001).
Interested in identifying a possible interrelation between c-Jun
levels and histone modiﬁcations on the Cyclin D1 promoter in
our EMT model, where both c-Jun and Cyclin D1 were shown to
be upregulated, we followed ChIP analysis in cells with reduced
expression levels of c-Jun. In this means, after reducing c-Jun
expression via c-Jun-speciﬁc siRNA, we followed ChIP analysis on
theCyclinD1promoter comparingH3K9/14ac levels under the con-
ditions of normal c-Jun expression (siControl) and reduced c-Jun
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Fig. 4. Repressive and active histone modiﬁcations on the Cyclin D1 and E-cadherin promoter in the Caco-H cell line. (A) Western blot (left) and total RNA levels (right)
of Cyclin D1 and E-cadherin in cell lines overexpressing oncogenic RAS. Reverse pattern of expression between Cyclin D1 and E-cadherin in Caco-H cells as compared to
Caco-2 was shown in both, mRNA and protein levels. (B) (left panel) Real-time PCR analysis of ChIP experiments on the promoter of Cyclin D1 and E-cadherin with chromatin
extracted from Caco-2 and Caco-H cells. Repressive histone modiﬁcation patterns of H3K27me3 and H3K9me2 and active histone modiﬁcation patterns of H3K4me3 and
H3K9/14ac were analyzed. Real-time PCR analysis of ChIP experiments on the promoter of Cyclin D1 and E-cadherin with chromatin extracted from Caco-2 and Caco-H cells.
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all ChIPs were performed with indicated antibodies or, as a negative control, in th
CR analysis of ChIP experiments on the promoter of Cyclin D1 to verify the occupa
ntibody. (C) Expression analysis of class II HDACs. In Caco-H cells all HDACs analyz
as less. Numbers below the WB bands represent the value of quantiﬁcation of the
xpression levels (c-Jun siRNA). Upon c-Jun downregulation (Fig. 6,
eft and central), the levels of H3K9/14ac on the Cyclin D1 promoter
egion decreased (Fig. 6, right) indicating a c-Jun contribution and
nvolvement in the recruitment or stabilization of acetyltranferase
omplexes on the Cyclin D1 promoter, thus regulating Cyclin D1
xpression upon RAS activation.
. Discussion
Epigenetic changes, among them, histone modiﬁcation are con-
idered to be markers for a variety of speciﬁc cellular processes
uch as transcription activation and DNA repair, or more global
unctions like DNA replication and chromosome condensation.
uring tumor progression, epigenetic events co-exist with genetic
lterations. Consequently, a signiﬁcant interest in the search andnce of any antibody. Results are normalized to Inputs. (B) (right panel) Real-time
f the promoter by methyltransferase enzymes EzH2. IP was performed using EzH2
played a strong upregulation whereas in Caco-K and Caco-BR clones the induction
normalized to tubulin.
identiﬁcation of new markers of histone modiﬁcations that are
altered during tumorigenesis has developed over the last fewyears.
Different parameters, as tumor progression stage, grade of tumor
differentiation, or gene mutations could associate with changes
in the global patterns of histone modiﬁcations in tumor cells.
Here we demonstrate, using cancer cell lines that some histone
markers of euchromatin i.e. H3K27me3 and H3S10p are altered
at global level as the tumor progresses. In the present study we
used a model of transformed colon cell lines that have undergone
epithelial–mesenchymal transition (EMT) in the case of Caco-H
or present alteration in the cell proliferation control in the case
of Caco-K and Caco-BR (Oikonomou et al., 2009). We decided to
focus on the EMT process because it represents an advanced pro-
cess of cancer cells associated with the metastasis and has recently
been reported to gain stem cell properties. Activating signalling
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Fig. 5. MEK–ERK RAS-activated signalling pathway upregulates Cyclin D1 expression and alters histone modiﬁcation patterns on its promoter region. (A) Real-time PCR
analysis (left panel) and end-point PCR analysis (central panel) of ChIP experiment analysing the H3K9–14ac modiﬁcation on the promoter of Cyclin D1 after inhibition of
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she MEK–ERK pathway. Western blot after inhibition of MEK–ERK pathway with U0
nd end-point PCR analysis (central panel) of ChIP experiment analysing the H3K9–
athway. Western blot analysis after inhibition of the MSK1 kinase activity with H8
umbers below the WB bands represent the value of quantiﬁcation of the spots no
athways through oncogenic Ha-RAS transformation leads to cells
resenting EMT phenotype. In stem cells the chromatin is globally
e-condensed and is enriched in acetylated histones, while repres-
ive heterochromatic marks like H3K9me3, are reduced (Meshorer
nd Misteli, 2006; Kimura et al., 2004). The open and dynamic sta-
us of chromatin is necessary for stem cell differentiation. Hence,
3K9/14ac could be a signature for both stem cell differentiation
nd tumor progression.
Changes in the chromatin appearance have been reported dur-
ng oncogene transformation (Chadee et al., 1999) and associated
ith the metastatic potential of tumor cells. Histone acetylation as
ne of the modiﬁcations related to the opened or closed state of
hromatin.
Our results indicate that at global level the H3K9/14ac is slightly
ower between Caco-2 intermediate adenoma cell line and Caco-
-transformed cells. We show a downregulation of this histone
arker when we analyzed at local level on the promoters of Cyclin
1 and E-cadherin, two genes involved in tumor progression. Fur-
hermore,we revealed that a possible explanation for the reduction
f acetylation in Caco-H cells was the strong induction of HDACs
nzymes. According to our results in a recent paper, using human
reast epithelial cell lines (MCF10A) transformed with Ha-RAS it
as been demonstrated (Park et al., 2008a,b) that the inhibition of
ig. 6. c-Jun contributes to stabilization/recruitment of acetyltransferases in CycD1 prom
f ChIP experiment analysing the levels of H3K9/14ac modiﬁcation on the promoter of Cy
o cells treated with siRNA control (siC). Results are normalized to inputs. (right panel) We
iRNA. Numbers below the WB bands represent the value of quantiﬁcation of the spots na ﬁnal concentration of 40M (right panel). (B) Real-time PCR analysis (left panel)
modiﬁcation on the promoter of Cyclin D1 after inhibition of the MEK–ERK–MSK1
nal concentration of 10M (right panel). All ChIP results are normalized to Inputs.
ed to tubulin.
histone deacetylase enzymes with the speciﬁc inhibitor apicidin
results in an increase of global acetylation of histone H3 and H4
and a decrease of Cyclin D1. Here we have also shown that the
MAPK–ERK–MSK1 signalling pathway is linked to the global lev-
els of H3K9/14ac as after blocking the Ha-RAS-activated MEK and
MSK1kinases theacetylation levels on theCyclinD1promoterwere
reduced.
Another histone modiﬁcation, H3K27me3 has been found to be
downregulated in some types of cancer, like ovarian, breast and
pancreatic cancers (Wei et al., 2008). In this study, H3K27me3 anti-
body was found to stain the periphery of the interphase nuclei in
different cell lines in agreement with the role of H3K27me3 as a
marker for facultative heterochromatin. Interestingly, the distri-
bution pattern of H3K27me3 in the nucleus of Caco-H cells was
modiﬁed, as its expression was lost from the peripheral nuclei area
while a granular pattern of expressionwas observed in the nucleus.
We suggest that this could be related either to the degree of dif-
ferentiation or to the EMT phenotype induced by Ha-RAS. EzH2
and JMJD3 are two methyl-protein-modifying enzymes that have
been described as H3K27me3 speciﬁc. EzH2 is a histone H3K27
methylase, which is highly expressed in metastatic prostate can-
cers, lymphomas and breast cancer and has been shown to provide
a proliferative advantage in primary cells (Kleer et al., 2003). Our
oter. Real-time PCR analysis (left panel) and end-point PCR analysis (central panel)
clin D1 after reduction of the c-Jun levels (siRNAc-Jun) in Caco-H cells as compared
stern blot analysis of the reduction levels of c-Jun in cells treated with c-Jun-speciﬁc
ormalized to actin.
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xperiments show that proliferative cells as Caco-H express high
NA and protein levels of EzH2 and this does not correlate with
ower global levels of H3K27me3. Interestingly, we followed by
hIP the presence of EzH2 on the promoter of Cyclin D1 and show
hat although EzH2 protein is overexpressed, the presence of EzH2
n the promoter of Cyclin D1 is reduced in Caco-H cells. Recently,
egative regulation of EzH2 function by AKT-mediated phosphory-
ation of a highly conserved serine residue, S21 of EzH2 has been
eported (Cha et al., 2005). Thismechanism facilitates the reduction
f H3K27 trimethylation by decreasing the afﬁnity of phosphory-
ated EzH2 to chromatin but without affecting the composition of
he polycomb–repressor complex. In fact, the AKT pathway was
bserved in a more active state in Caco-H as compared to Caco-2
ells. Furthermore, additional independent functions have as well
een suggested for EzH2 that do not involve H3K27 methylase
Martin et al., 2006). The presence of H3K27me3 on DNA con-
ributes to chromatin compaction (Margueron et al., 2008) and
rotects the chromatin from demethylases like the H3K27me3-
peciﬁc demethylase JMJD3 (Hong et al., 2007).
The dynamic balance of opposing histone-modifying enzymes
s critical for the regulation of cell proliferation. It has been shown
reviously that HDAC1, HDAC2 and HDAC3 are highly expressed in
subset of colorectal carcinomas and associated with proliferative
roperties of tumors and poor survival. Preferential deacetylation
f H3K9 has been reported for HDAC1 and HDAC3 in knock-down
xperiments (Zhang et al., 2004) while growth reduction was
bserved after knock-down of these enzymes in several colon can-
er cell lines (Wilson et al., 2006; Zhu et al., 2004; Spurling et al.,
008). However, the expression analysis of different HATs and the
lass I HDACs (data not shown) in different cell lines does not pro-
ide a clear explanation for the increased H3K9/14ac levels in cell
ines that express oncogenic RAS. Here, we report that the RAS
ffect onH3-acetylation is possibly due to the action of human class
I HDAC enzymes. Increased expression levels of HDAC 4,5,7,9 in
aco-H cells could be important for the decrease in H3-acetylation
bserved in Caco-H cells, as reported by Ozdag˘ et al. (2006).
It is well known that Ras proteins have essential roles in con-
rolling theactivityofmultipledownstreameffector-pathways that
egulate normal cellular proliferation.Moreover, Ras activation and
ore speciﬁcally Ha-RAS activation, and herewith cancer progres-
ion and EMT, results in increased levels of Cyclin D1 and at the
ame time in decreased levels of E-cadherin. Importantly, regula-
ion of the Cyclin D1 expression by different transcription factors
s well reported but the interplay between transcription factors
nd histone modiﬁcations is not yet well understood. Similarly, the
xpression of E-cadherin and therefore its promoter activity is reg-
lated by interplay between CpG island methylation and histone
odiﬁcations (Dumont et al., 2008; Lombaerts et al., 2006).
Here, we present evidence supporting the idea that onco-
enic Ha-RAS affects cell proliferation and cancer progression
hrough alteration of histone modiﬁcation patterns on gene
romoters involved in these processes. Thus, the epigenetic modi-
cation marking repressed gene promoters H3K27me3 was found
ecreased on the promoter of Cyclin D1 in Caco-H cells as com-
ared to Caco-2 cells thoughEzH2was upregulated,while the same
istone modiﬁcation was found increased on the promoter of E-
adherin, matching their inverse expression patterns in these cells.
imilarly, the other mark for repressed gene promoters, H3K9me2,
howed similar results indicating that indeed the presence of these
epressive marks can be associated with the expression levels of
ertain genes.The presence of histone modiﬁcations for active gene promot-
rs did not absolutely correlate with the inverse expression proﬁle
f the two genes E-cadherin and Cyclin D1. Nevertheless, the
ecreased levels of marks of active gene promoters, H3K9me2 and
3K9–14ac, matched the low expression of E-cadherin in Caco-Hiochemistry & Cell Biology 42 (2010) 911–920 919
cells as compared to Caco-2 cells. On the other hand, Cyclin D1
promoter occupancy by the same active marks did not correlate, as
both were slightly decreased in Caco-H cells as compared to Caco-
2. Interestingly, it has been reported that the presence of active
marks may serve as a way to inhibit transcription silencing of a
gene. Importantly, the protein levels of Cyclin D1 vary during cell
cycleprogression, composing the further studyof thehistonemodi-
ﬁcationson thepromoterofCyclinD1onspeciﬁc timepointsduring
the G1- to S-phase transition of the cell cycle, of great importance.
Further on, deciphering the regulation of Cyclin D1 on the
promoter level, deregulation of Cyclin D1 expression through
MEK–ERK pathway was shown to be mediated by changes in the
levels of active histone mark H3K9/14ac. This might present a
supplementary mechanism for the regulation of the expression of
Cyclin D1 in this particular EMT model.
All this together highlights the complexity of gene regulation
and demonstrates how effectors of EMT, such as Ha-RAS, might
regulate speciﬁc gene expression by epigenetic rearrangement.
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